FIREFISH trial in infants with type 1 spinal muscular atrophy: Risdiplam has demonstrated motor improvement
Positive results from the pivotal Part 2 of the FIREFISH study, evaluating Risdiplam in infants aged 1-7 months with type 1 spinal muscular atrophy ( SMA ) were announced.
The primary outcome measu ...
read article